SAFE Fertility Clinic at PGDIS 2026: Research Proves High Pregnancy Success with PGTseq-A for Intermediate Copy Number (ICN) Embryos

SAFE Fertility Clinic, in collaboration with Next Generation Genomic (NGG), is proud to announce a significant achievement as their latest research has been selected for presentation at the prestigious 23rd International Conference on Preimplantation Genetics (PGDIS) in Shanghai, China. This recognition underscores the clinical utility of PGTseq-A technology in enhancing embryo selection precision, particularly for embryos with Intermediate Copy Numbers (ICN).

Overcoming Embryo Selection Limits with PGTseq-A

Standard PGT-A testing often faces challenges in clearly classifying embryos with "intermediate" chromosomal results. Historically, embryos falling into the range between normal and abnormal were difficult to prioritize for transfer, as they were not 100% normal (No Aneuploidy Found) but did not show clear abnormalities (Aneuploidy).

The core of this research utilizes PGTseq-A, a high-resolution chromosomal screening innovation from Juno Genetics (USA). This advanced technology provides a deeper and more detailed analysis of embryos with Intermediate Copy Numbers (ICN), directly impacting the accuracy of clinical decisions and significantly improving the chances of a successful pregnancy.

Research Download

Clinical Comparative Analysis of Pregnancy Outcomes Between Embryos
with Intermediate Copy Numbers and No Aneuploidy Found Embryos

ICN Embryos: Higher Potential Than Previously Thought

The scientific team conducted a comparative study of pregnancy outcomes and found that embryos with Intermediate Copy Numbers (ICN) screened using PGTseq-A demonstrated highly satisfactory pregnancy rates. Most importantly, there was no significant difference in success rates when compared to embryos classified as perfectly normal.

This is a significant clinical finding for those undergoing assisted reproductive technologies like IVF/ICSI. It ensures that embryos previously classified as uncertain are not automatically excluded from transfer consideration, allowing for more efficient treatment planning, reducing the number of stimulation cycles, and lowering long-term treatment costs.

The international acceptance of this research reflects the dedication and expertise of the research committee and the leadership team, headed by Wiwat Quangkananurug, M.D., Founder and CEO of SAFE Fertility Group PCL., and Sujin Chanchamroen, Chief Laboratory Officer of SAFE Fertility Group PCL., along with the esteemed scientific team:

Patthorn Jaikla
Wanwisa Suksalak
Nuntiporn Nunthanasup
Wipawee Tangsee
Chutimon Pomsuwan
Nadsarin Tochoowong
Manipha Tantipoj
Navarat Siriprasertchok

The presentation of this work reaffirms that PGTseq-A is a vital solution in resolving chromosomal screening uncertainties, transforming "intermediate" results into tangible opportunities for clinical success.

SAFE Fertility Clinic remains committed to the continuous development of reproductive technology to maintain the highest standards of care and deliver successful outcomes for every family that trusts in our expertise.

Back